CSL lifts profit to $4b, tips further double-digit growth

Australian pharmaceutical giant CSL Limited (ASX: CSL) has boosted net profit by 20 per cent to US$2.64 billion ($4.0http://www.businessnewsaustralia.com/1 billion) in FY24, with pumped up margins from its immunoglobins portfolio driving growth and poised to deliver another big result in the…